Baker Bros. Advisors 13F: Adds $13M to Alumis (ALMS) Stake

Baker Bros. Advisors Boosts Position in Alumis Inc.

Baker Bros. Advisors filed its latest Form 13F with the Securities and Exchange Commission, revealing a larger stake in clinical-stage biopharmaceutical company Alumis Inc. (NasdaqGS: ALMS). During the quarter, the investment firm added 450,000 shares to its portfolio. That move marked a 28.8% increase, lifting its total holdings to 2,012,500 shares. Based on the reported period, the value of that stake stood at approximately $55.9 million.

Alumis Inc. Stock Performance and Recent Trading

Shares of Alumis Inc. recently traded near $27.78. The company's stock has seen strong momentum over the past year, sitting far above its 52-week low of $3.76 and approaching its 52-week high of $31.35. Because Form 13F filings look backward at holdings from the close of the reporting period, these numbers reflect positions held as of May 15, 2026, and may not represent the firm's exact share count today.

Wall Street Analyst Updates and Price Targets

Wall Street firms have kept a close eye on the biotech developer through late summer and early autumn. On September 3, 2026, Guggenheim downgraded the stock to a neutral rating. Just a day earlier on September 2, 2026, Oppenheimer maintained an outperform rating while adjusting its price target to $37.00 from $55.00. On the same date, Wells Fargo kept an overweight rating with a $25.00 target, and Morgan Stanley maintained an overweight rating while moving its target to $29.00 from $39.00. Also on September 2, 2026, HC Wainwright & Co. upgraded the stock to a buy rating with a $15.00 target. Earlier in August, HC Wainwright & Co. had reiterated a neutral rating with a $25.00 target on both August 3 and August 14. Overall, the stock carries a consensus strong buy recommendation with eight analyst opinions and a mean price target of $32.12.

Inside Alumis Inc. and Its Pipeline

Alumis Inc. focuses on building targeted medicines for immune system disorders. Headquartered in South San Francisco, California, the company develops treatments like envudeucitinib for plaque psoriasis and systemic lupus erythematosus, alongside programs targeting neurodegenerative and thyroid eye diseases. With 237 employees, the clinical-stage firm continues to advance its pipeline through early and mid-stage trials.

What to Watch Next for Alumis Inc.

Investors tracking Alumis Inc. will want to keep an eye out for upcoming institutional disclosures and the company's next scheduled earnings report on November 12, 2026. As always, 13F reports offer a retrospective look at portfolio moves rather than live trading data, making future filings essential for tracking where major funds land next.